2,168 reports of this reaction
4.3% of all IXEKIZUMAB reports
#4 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #4 most commonly reported adverse reaction for IXEKIZUMAB, manufactured by Eli Lilly and Company. There are 2,168 FDA adverse event reports linking IXEKIZUMAB to INJECTION SITE ERYTHEMA. This represents approximately 4.3% of all 50,855 adverse event reports for this drug.
Patients taking IXEKIZUMAB who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is moderately reported among IXEKIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to injection site erythema, the following adverse reactions have been reported for IXEKIZUMAB:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 2,168 FDA reports for IXEKIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 4.3% of all adverse event reports for IXEKIZUMAB, making it a notable side effect.
If you experience injection site erythema while taking IXEKIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.